miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. - Wikidata - awgldk - TriplyDB

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

http://www.wikidata.org/entity/Q34996775

about

Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer?miRNAs in human cancer The role of microRNAs in bladder cancer The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer How microRNAs influence both hereditary and inflammatory-mediated colon cancers The Role of MicroRNAs in Diabetic Complications-Special Emphasis on Wound Healing Sheep, wolf, or werewolf: cancer stem cells and the epithelial-to-mesenchymal transition MiR-200, a new star miRNA in human cancer Clinical and pathological implications of miRNA in bladder cancer The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance The emerging molecular machinery and therapeutic targets of metastasis Regulating miRNA by natural agents as a new strategy for cancer treatment Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy Preliminary Analysis of the Expression of Selected Proangiogenic and Antioxidant Genes and MicroRNAs in Patients with Non-Muscle-Invasive Bladder Cancer The Regulatory Role of MicroRNAs in EMT and Cancer Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation.XIAP BIR domain suppresses miR-200a expression and subsequently promotes EGFR protein translation and anchorage-independent growth of bladder cancer cell miR-8 modulates cytoskeletal regulators to influence cell survival and epithelial organization in Drosophila wings.Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity.Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels Module network inference from a cancer gene expression data set identifies microRNA regulated modules MicroRNAs as biomarkers associated with bladder cancer.MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway Systems biology of interstitial lung diseases: integration of mRNA and microRNA expression changes.Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis Effects of miRNA-200b on the development of diabetic retinopathy by targeting VEGFA gene.Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer A ten-microRNA expression signature predicts survival in glioblastoma Implication of microRNAs in drug resistance for designing novel cancer therapy Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness.Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma multiforme.Biomarkers for drug-induced renal damage and nephrotoxicity-an overview for applied toxicology.Cysteine-rich 61-connective tissue growth factor-nephroblastoma-overexpressed 5 (CCN5)/Wnt-1-induced signaling protein-2 (WISP-2) regulates microRNA-10b via hypoxia-inducible factor-1α-TWIST signaling networks in human breast cancer cells

P2860

Q24299613-CCF102C5-E547-4871-97A8-F148F5B5EA45 Q24610880-0349405B-2E2D-4330-91A2-17C8229FF8C4 Q24617121-6AC5AB4B-2A2B-43B7-9575-DDA79BD0CF04 Q24628889-C5A05EC0-0DE9-43F6-B386-CDA34C9D8C85 Q26744149-BB9FFB6A-1273-4127-B6E4-720920A034AA Q26770682-A073FAA9-D071-48D8-99AC-AB54399B358D Q26771263-7FAB634E-BD9B-4706-B8FE-02D202BE0F22 Q26796592-6108EFB4-1559-43F9-B216-C5EB96EEC5FB Q26798147-149A797D-16D2-4B1D-8E96-53AFC3DA30ED Q26823451-E4B13344-86CA-4AA8-BFAF-D0A235100BF1 Q26827627-2594E0E5-FAA7-4A50-BD4C-F982BA52220A Q26864979-D3A44FCC-03E1-4190-9B59-34FBB43F4953 Q27004023-D5C24C02-4642-43CC-B0FC-5647F9DE1A64 Q27004262-6D037A47-A813-4099-B229-892490C9E776 Q27010233-35232B13-1852-4AA4-85CC-BFB9A92F496C Q27015111-8253551E-A7A5-4C23-9AFA-3F27041F3FA2 Q27022207-AF07AAE2-66D4-453C-8968-652C530CDF54 Q27026972-B6B770C4-BEB9-4EBD-8BC1-7F4D02C9E085 Q27026986-51CA8DD9-EC1D-4EB0-B78E-559EB9FB1F3A Q28083742-5D114B67-00EE-4822-855C-F8A9D26CB903 Q28390776-0569F27C-CBE6-4282-98DE-15C9CDB7D562 Q28391426-CE8EC461-6EF8-41F4-B9D4-9B9E1A794F1F Q28730032-3567B2CB-3CE3-4F94-8025-538FB6F2263C Q30354484-104F4C77-63D8-4B1C-9675-D607A82E090E Q30359720-04263F01-A69F-4EBE-BCA2-3EA1D01BFD02 Q30498197-C72D1796-8D7E-466C-B73C-04C32343A981 Q30502172-630131AC-1775-4FA1-B1B4-8B0ED0B0F887 Q33564117-082551ED-F3F0-42ED-B36D-1A8413F111D5 Q33642335-81903ADD-A1F1-412A-B90D-2DC50851A59E Q33733659-15DA3305-62AB-4B93-A98E-2744BF261336 Q33795193-3B9608F6-8DCC-40B9-8E7F-95A65B48C657 Q33798322-92E999D5-7714-46C2-9EAB-59AF81194E1E Q33833070-B5C24893-7B09-46A7-B435-7CEF7195C7B7 Q33838491-627E30BF-B1AA-47E3-A185-051C539590C9 Q33869822-A911C35E-A631-4497-9B92-4B2543C004D3 Q33903223-D9124CCA-8170-469C-84D6-6466B41667B4 Q33911224-9159EA93-E78A-4857-B428-51E392BBA488 Q33945781-0FAA0A96-7B75-4679-B825-3D810D4FBFF7 Q34039254-A4CC079D-532A-413B-B556-25FD98E3FA62 Q34054835-B888A16D-AF5A-49E7-AAD0-F1DD43A2E971

P2860

miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy.

http://www.wikidata.org/entity/Q34996775

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

miR-200 expression regulates e ...... rowth factor receptor therapy.

@ast

miR-200 expression regulates e ...... rowth factor receptor therapy.

@en

miR-200 expression regulates e ...... rowth factor receptor therapy.

@nl

type

label

miR-200 expression regulates e ...... rowth factor receptor therapy.

@ast

miR-200 expression regulates e ...... rowth factor receptor therapy.

@en

miR-200 expression regulates e ...... rowth factor receptor therapy.

@nl

prefLabel

miR-200 expression regulates e ...... rowth factor receptor therapy.

@ast

miR-200 expression regulates e ...... rowth factor receptor therapy.

@en

miR-200 expression regulates e ...... rowth factor receptor therapy.

@nl

P1433

Q34996775-50420BA4-3466-4CD6-AA35-DEA940578E01

P1476

Q34996775-72A7B841-12C7-450F-ADF2-6E877FC5F536

P2093

Q34996775-02C4682F-949B-4C47-B883-86CC1972FB21

Q34996775-21D837C3-3CB1-47BB-9E4A-353DC4CE0C9E

Q34996775-4F02F24F-FC06-404C-98CD-017EC0AFC6C9

Q34996775-59A74C8E-49A4-43C4-8FCE-C5BD449D55BD

Q34996775-6BF2463A-A00D-4E51-B792-AD806038A0D9

Q34996775-89709079-8A34-45E1-B042-A9E1B2348BCC

Q34996775-C0682E1B-62C5-4421-A93B-F4003F6727C9

Q34996775-CFA1126F-7E68-4A13-9447-7933C0D5CB61

Q34996775-DE32CFD8-F95F-4E2D-889D-814598F6CE8B

Q34996775-E0C9E667-460A-4C30-9DA0-EBC0B9B83754

P2860

Q34996775-0536C0F7-F95B-4E53-81DC-E90E0DB0FDCD

Q34996775-07B6B947-0F05-4E4C-8F50-31876BDA6933

Q34996775-093BE98B-30D0-43B2-AED0-7CAA577852E3

Q34996775-0F3D3C30-3324-4D7B-AE94-A243AB612A64

Q34996775-120708FC-E1A3-4435-9849-23A427A58285

Q34996775-1FB734DA-AE2D-4848-9C41-192E60B0684F

Q34996775-25A05E00-42FE-40B6-8B6E-3783B762F98D

Q34996775-2903B50D-DC57-4211-9A7D-2E64F9B1418E

Q34996775-2B1F4EC3-FD09-44AF-AEA9-34AEE983EB91

Q34996775-37CCC8AD-2961-4D3B-9D4B-22DB044A9F99

P304

Q34996775-E2CE368B-6CCA-4D07-AA06-4CB0CDF3C860

P31

Q34996775-A64FFD01-0046-404F-B90A-CB5F64C524C3

P356

Q34996775-F71776EB-DBBE-4F56-926D-3E35D6306903

P407

Q34996775-CAF7918B-4799-4792-9573-96231FE7ADCA

P433

Q34996775-738FAD73-11FE-45D0-BB12-771DDBE1669C

P478

Q34996775-3C20E27C-5898-48A0-AA7B-3EECFF204ECF

P50

Q34996775-2B110B27-F46F-4D55-913D-87ACB40C4A96

P577

Q34996775-77C08390-8508-4A6E-AFCB-94211BFC863C

P5875

Q34996775-A499627C-750D-4765-B582-2D4A350004A2

P698

Q34996775-9D3AA0A5-1FA7-4FB3-8CCC-1AA8AEFE5889

P932

Q34996775-D28C5739-1CFE-40D9-9C7B-380185C90C7E

P356

1078-0432.CCR-08-2245

P1433

Clinical Cancer Research

P1476

miR-200 expression regulates e ...... rowth factor receptor therapy.

@en

P2093

Ameeta Arora

http://www.w3.org/2001/XMLSchema#string

Arlene Siefker-Radtke

http://www.w3.org/2001/XMLSchema#string

Colin Dinney

http://www.w3.org/2001/XMLSchema#string

David McConkey

http://www.w3.org/2001/XMLSchema#string

Hua Wang

http://www.w3.org/2001/XMLSchema#string

Liana Adam

http://www.w3.org/2001/XMLSchema#string

Menashe Bar-Eli

http://www.w3.org/2001/XMLSchema#string

Meng Zhong

http://www.w3.org/2001/XMLSchema#string

Milena Nicoloso

http://www.w3.org/2001/XMLSchema#string

Wei Qi

http://www.w3.org/2001/XMLSchema#string

P2860

Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stre

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity

Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain

The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

The epithelial-mesenchymal transition generates cells with properties of stem cells

Phosphotyrosine interactome of the ErbB-receptor kinase family

Oncomirs - microRNAs with a role in cancer

MicroRNA signatures in human cancers

P304

5060-5072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-2245

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

George A. Calin

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733353

http://www.w3.org/2001/XMLSchema#string

P698

19671845

http://www.w3.org/2001/XMLSchema#string

P932

5938624

http://www.w3.org/2001/XMLSchema#string